18 research outputs found

    Current hepatitis A status in Canada

    Get PDF
    Hepatitis A, caused by the hepatitis A virus, occurs most frequently in developing countries, but also causes sporadic cases or outbreaks in industrialized countries. The most common route of transmission is fecal-oral. The incidence of hepatitis A varies with geography, and economic and environmental conditions. The epidemiological pattern of the disease has changed with improvements in hygiene and economic conditions. The incidence and prevalence of hepatitis A has decreased, while the average age of exposure and subsequent infection has increased. The present report describes the current status of hepatitis A in Canada. The incidence rate of reported cases in Canada varies from over 10/100,000 (1991) to 3.6/100,000 (1998), and is higher in males, 4.7/100,000 (1998), than in females, 2.5/100,000 (1998). The highest reported hepatitis A rates are in age groups 30 to 39 years and 40 to 59 years, and in British Columbia. Such information is important for assessing current immunization approaches and for decision-making about new preventive strategies against hepatitis A in Canada

    Epidemiology of hepatitis B in Canada

    No full text
    OBJECTIVE: To provide a current and comprehensive review of the epidemiology of hepatitis B virus (HBV) in Canada

    Genetic characterization of the hemagglutinin gene of influenza B virus which predominated in the 1985/86 Canadian influenza season

    No full text
    OBJECTIVE: To characterize the hemagglutinin (HA) gene of B/Canada/3/85, a prototype strain of influenza B virus variants that emerged in the 1984/85 influenza season and predominated in the 1985/86 season in Canada

    Prediction of Hepatitis C Burden in Canada

    Get PDF
    To assess the risk of hepatitis C in Canada and to predict the burden that this disease may pose to the Canadian society in the near future, expected numbers of persons at different stages of the disease currently and in the next decade were estimated by simulation using a published hepatitis C natural history model with no treatment effect being applied. Based on the estimate of 240,000 persons who are currently infected with the hepatitis C virus in Canada, the simulation analysis demonstrated that the number of hepatitis C cirrhosis cases would likely increase by 92% from 1998 to the year 2008. It was also projected that the number of liver failures and hepatocellular carcinomas related to hepatitis C would increase by 126% and 102%, respectively, in the next decade. The number of liver-related deaths associated with hepatitis C is expected to increase by 126% in 10 years. The medical and social care systems in Canada may not be ready to support these large increases. These results highlight the importance of both the control of disease progression of hepatitis C virus-infected persons and the primary prevention of hepatitis C infections in Canada

    Applying DALYs to the burden of infectious diseases

    No full text
    corecore